Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 6/20 | 1.00 |
| ▸ | HTR1A | P08908 | 3/20 | 0.69 |
| ▸ | DRD2 | P14416 | 3/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8869546 | 0.93 | SLC6A4 (0.87) | SLC6A4HTR1ADRD2 | |
| Oxalic Acid SCHEMBL8869051 | 0.87 | SLC6A4 (0.77) | SLC6A4HTR1ADRD2 | |
| SCHEMBL4673516 | 0.86 | SLC6A4 (0.75) | SLC6A4 | |
| SCHEMBL8869768 | 0.86 | SLC6A4 (0.75) | SLC6A4HTR1ADRD2 | |
| SCHEMBL11313868 | 0.85 | HTR1A (0.75) | SLC6A4HTR1ADRD2 | |
| SCHEMBL13323539 | 0.84 | SLC6A4 (1.00) | SLC6A4HTR1A | |
| SCHEMBL4670946 | 0.84 | SLC6A4 (0.72) | SLC6A4 | |
| SCHEMBL16801779 | 0.82 | SLC6A4 (0.70) | SLC6A4HTR1ADRD2 | |
| SCHEMBL4178633 | 0.82 | SLC6A4 (0.70) | SLC6A4HTR1ADRD2 | |
| SCHEMBL18324680 | 0.82 | SLC6A4 (0.70) | SLC6A4HTR1ADRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0003200-B1 | TETRAHYDROPYRIDINYL INDOLE DERIVATIVES AND THEIR SALTS FOR USE IN A METHOD FOR THERAPEUTIC TREATMENT OF THE HUMAN OR ANIMAL BODY AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ROUSSEL-UCLAF (FR) | 1986-08-13 | — | — | EP | claimed |
| US-4195081-A | Treating psychic disorders with tetrahydropyridin-4-yl-1H-indoles | ROUSSEL UCLAF (FR) | 1980-03-25 | — | — | US | claimed |
| US-20240376052-A1 | N-SUBSTITUTED INDOLE DERIVATIVES AS SEROTONERGIC AGENTS USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | MINDSET PHARMA INC. (CA) | 2024-11-14 | — | — | US | disclosed |
| WO-2023019366-A1 | N-SUBSTITUTED INDOLE DERIVATIVES AS SEROTONERGIC AGENTS USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | MINDSET PHARMA INC. (CA) | 2023-02-23 | — | — | WO | disclosed |
| WO-2023019366-A1 | N-SUBSTITUTED INDOLE DERIVATIVES AS SEROTONERGIC AGENTS USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | MINDSET PHARMA INC. (CA) | 2023-02-23 | — | — | WO | disclosed |
| US-20070225269-A1 | Use of (3-(1-(3-Phenyl-Propenyl)-Piperidin-4-Yl)-2,3-Dihydro-Indol-1-Yl)-(Pyridin-4-Yl)-Methanonone Derivatives and Related Compounds as Insecticides | SYNGENTA CROP PROTECTION, INC. | 2007-09-27 | — | — | US | disclosed |
| US-20070225269-A1 | Use of (3-(1-(3-Phenyl-Propenyl)-Piperidin-4-Yl)-2,3-Dihydro-Indol-1-Yl)-(Pyridin-4-Yl)-Methanonone Derivatives and Related Compounds as Insecticides | SYNGENTA CROP PROTECTION, INC. | 2007-09-27 | — | — | US | disclosed |
| US-6358972-B1 | FOR THERAPY OF MIGRAINE | ELI LILLY AND COMPANY | 2002-03-19 | — | — | US | disclosed |
| WO-2000000490-A2 | 5-HT1F AGONISTS | ELI LILLY AND COMPANY (US) | 2000-01-06 | — | — | WO | disclosed |
| US-4237048-A | COLORFASTNESS; FOR DYEING NATURAL AND SYNTHETIC FIBERS | BAYER AKTIENGESELLSCHAFT (DE) | 1980-12-02 | — | — | US | disclosed |
| US-4195081-A | Treating psychic disorders with tetrahydropyridin-4-yl-1H-indoles | ROUSSEL UCLAF (FR) | 1980-03-25 | — | — | US | disclosed |
| US-4105655-A | PHENYL-AZO-ANILINO DYESTUFF | BAYER AKTIENGESELLSCHAFT (DE) | 1978-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240376052-A1 | N-SUBSTITUTED INDOLE DERIVATIVES AS SEROTONERGIC AGENTS USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | TPH1, HTR5A, TPH2 | SLC6A4 16/4885HTR1A 4/4885DRD2 55/4885 |
| US-20070225269-A1 | Use of (3-(1-(3-Phenyl-Propenyl)-Piperidin-4-Yl)-2,3-Dihydro-Indol-1-Yl)-(Pyridin-4-Yl)-Methanonone Derivatives and Related Compounds as Insecticides | CHRM1, NPY1R, MRM1 | SLC6A4 4269/4885HTR1A 206/4885DRD2 738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.